News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
International Business is expected to register double-digit growth in constant currency terms
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated
